Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AH 008

Next Previous
Drug Profile

AH 008

Latest Information Update: 24 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnHorn Medicines
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Peripheral neuropathies

Most Recent Events

  • 14 Nov 2025 AH 008 is available for licensing as of 14 Nov 2025. https://www.anhornmed.com/
  • 14 Nov 2025 Preclinical trials in Peripheral neuropathies in Taiwan (unspecified route)
  • 14 Nov 2025 AnHorn Medicines plans to file an IND application with the US FDA for Peripheral neuropathies in fourth quarter of 2025 (AnHorn Medicines pipeline, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top